Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

Author： Barbee Meagan S.   Nooka Ajay   Kaufman Jonathan L.   Kim Sungjin   Chen Zhengjia   Heffner Leonard T.   Lonial Sagar   Harvey R. Donald  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|6|853-862

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.6, 2015-03, pp. : 853-862

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Carfilzomib: In Relapsed, or Relapsed and Refractory, Multiple Myeloma

By McCormack Paul L.  

Drugs, Vol. 72, Iss. 15, 2012-10 ,pp. : 2023-2032

Adis International

Access to resources Recommend Favorite

High-dose tamoxifen is not a feasible option in patients with relapsed or refractory multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions

By Offidani Massimo   Corvatta Laura   Morabito Fortunato   Gentile Massimo   Musto Pellegrino   Leoni Pietro   Palumbo Antonio  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 779-793

Informa Healthcare

Access to resources Recommend Favorite

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

By van de Donk Niels WCJ   Lokhorst Henk M  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1569-1573

Informa Healthcare

Access to resources Recommend Favorite

Feasibility of myeloablative allogeneic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 363-365

John Wiley & Sons Inc

Access to resources Recommend Favorite